home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550013.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
1KB
|
27 lines
Document 0013
DOCN M9550013
TI Pathology and pathophysiology of primary pulmonary hypertension.
DT 9505
AU Rubin LJ; Department of Medicine, University of Maryland School of;
Medicine, Baltimore.
SO Am J Cardiol. 1995 Jan 19;75(3):51A-54A. Unique Identifier : AIDSLINE
MED/95142027
AB Primary pulmonary hypertension (PPH) is at present little understood. It
is characterized by extensive remodeling of the pulmonary vasculature,
with consequent deleterious hypertrophic changes in the right ventricle.
Median survival is 2.6 years, although this varies with the severity of
right heart failure. Although PPH can occur at any age and in either
sex, it primarily affects young to middle-aged women. A genetic
predisposition appears to be a component of this disease, triggered by
presentation of a stimulus (e.g., drugs or HIV infection). Symptomatic
presentation includes exertional dyspnea, chest pain, and syncope. At
present, therapy consists principally of anticoagulation, calcium
antagonists, nitric oxide inhalation, or continuous intravenous
prostacyclin.
DE Human Hypertension, Pulmonary/*PATHOLOGY/*PHYSIOPATHOLOGY Support,
U.S. Gov't, P.H.S. JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).